article
Championing UK ATMP clinical trials
In this Q&A, Jacqueline Barry, Chief Clinical Officer for Cell and Gene Therapy Catapult, elucidates on how the Advanced Therapy Treatment Centre (ATTC) Network can strengthen UK ATMP clinical trials.
List view / Grid view
Innovate UK
news
UK advanced therapies to get £17.9 million boost
The initiative aims to support the UK as a location of choice for advanced therapy research, according to the Cell and Gene Therapy Catapult.
news
Joint investment to accelerate UK sustainable biomanufacturing
One project supported through £11.5 million investment will focus on biocatalytic nitro-reductions in scalable continuous flow reactors, using paracetamol as a case study.
news
Pioneering PAT to improve gene therapy AAV manufacture
The CGT Catapult and two other collaborators have agreed to work together and use advanced process analytical technologies (PAT) to improve the process and efficiency of gene therapy AAV manufacturing.
news
New medicines manufacturing centre to enhance UK talent
Part of the £650 million ‘Life Sci for Growth’ funding package announced in May 2023, £5.5 million is set to deliver a new UK Medicines Manufacturing Skills Centre of Excellence to boost the skills of talent in the life sciences sector.
news
New UK drug delivery centre to support RNA therapeutic development
To develop new lipid nanoparticle formulations for RNA therapeutic delivery technologies, CPI and partners are working to establish a new UK Intracellular Drug Delivery Centre.
news
Life sciences sector to receive £650 million funding
Funding to support the UK's life sciences manufacturing, skills and infrastructure has been announced as part of a £650m growth package.
news
Catapult presents vision for UK’s cell and gene therapy future
To ensure the UK’s prominence in the cell and gene therapy arena, the CGT Catapult has published a roadmap for the research and adoption of these cutting-edge therapies.
![Researcher looking at an experiment [Credit: Unsplash].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Bell-advanced-therapies-feature-300x278.jpg)
![Researcher looking at an experiment [Credit: Unsplash].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Bell-advanced-therapies-feature.jpg)
article
UK at the forefront of advanced therapies
Advanced therapies are a ground-breaking new class of medicines that use gene therapy, cell therapy or tissue engineering to treat disease and injury. Rachel Bell, Trainee Patent Attorney at Marks & Clerk, and Ceri Roberts, Scientific Training Manager – Cellular and Molecular Therapies at NHS Blood and Transplant, discuss some…
news
Two awards granted to recognise work in bioprocessing industry
The UK BioIndustry Association’s bioProcessUK conference saw two awards given to Sharon Grimster and Dr Sarah Goulding for their work in the bioprocessing sector.
news
Biotech firm awarded for approach to drug development
A UK based biotech firm has been awarded a grant to develop a treatment for osteoarthritis, after promising results from a Phase I trial...
news
National Physical Laboratory re-launched to improve access to health innovations
NPL's new approach informed by government priorities, consultancy with industry and the NHS, and a century of expertise, will see it focus on some of the world’s biggest health challenges, from supporting the diagnosis and treatment of cancer and dementia, to reducing attrition rates in drug development, to creating new…
news
Cypralis granted new Innovate UK feasibility stage award for chronic pancreatitis
Cypralis, has been awarded funding by Innovate UK to develop cyclophilin inhibitors targeting fibrotic diseases...
